Enhanced Palliative Care in MDS and AML
Impact of Enhanced Haematology Palliative Care Services in Patients With Myelodysplastic Syndrome and Acute Myeloid Leukaemia
Sponsor: The University of Hong Kong
Listed as NCT04226768, this NA trial focuses on Myelodysplastic Syndromes and remains ongoing. Sponsored by The University of Hong Kong, it has been updated 7 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Nov 2024 — Present [monthly]
Unknown NA
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Nov 2022 — Jul 2024 [monthly]
Active Not Recruiting NA
Status: Unknown Status → Active Not Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Recruiting NA
-
Feb 2020 — Jan 2021 [monthly]
Recruiting NA
First recorded
Jan 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The University of Hong Kong
For direct contact, visit the study record on ClinicalTrials.gov .